-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the evening of February 21st, Biotech issued an announcement stating that it had recently received the "Drug Supplementary Application Approval Notice" for adalimumab injection (trade name: Glaly®) approved and issued by the State Food and Drug Administration.
Data show that Glorious® is a biosimilar of adalimumab developed by Biotech, which is a recombinant fully human monoclonal antibody expressed by CHO cells.
As of the announcement date, the approved indications for Glorious® are ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, uveitis and plaque psoriasis in children.